

- **Name:** Sang-Yoon Lee
 - **Current Position & Affiliation:** Chief Medical Officer of Interpart Bio Convergence Center
 - **Country:** Korea
-

• Educational Background:

Seoul National University College of Medicine

Residency at Department of Internal Medicine, Seoul National University Hospital

Clinical Fellow at Hematology/Medical Oncology, Seoul National University Hospital

• Professional Experience:

Pfizer, 2007 – 2015, Clinical/Medical Affairs member of Global Development Teams of Dacomitinib and Crizotinib, (last position) Oncology Japan Medical Affairs Director

Samsung BioEpi 2015-2016, Oncology Study Physician

Crystal Genomic 2016-2017, CMO

HANDOK, 2017-2020, Head of Clinical Research Science

Interpark Bio Convergence Center, 2020 -, CMO

• Professional Organizations:

Korean Cancer Association

Korean Society of Medical Oncology

Korean Society of Pharmaceutical Medicine

American Society of Clinical Oncology

International Society for the Study of Lung Cancer

• Main Scientific Publications:**1. Real-world use of Sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.**

Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S, Lee SY (corresponding author).

Jpn J Clin Oncol. 2015 Jun;45(6):576-83.

2. Safety and efficacy of Dacomitinib in Korean patients with KRAS wild-type advanced non-small cell lung cancer refractory to chemotherapy and Erlotinib or Gefitinib: a phase I/II trial.

Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.

J Thorac Oncol. 2014 Oct;9(10):1523-31.

3. Phase 1 study of Sunitinib plus Capecitabine/Cisplatin or Capecitabine/Oxaliplatin in advanced gastric cancer

Lee KW, Park SR, Oh DY, Park YI, Khosravan R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, Bang YJ.

Invest New Drugs. 2013 Dec;31(6):1547-58. Epub 2013 Oct 4.

4. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients; a multicenter, cross-sectional study.

Oh DY, Crawford B, Kim SB, Chung HC, McDonald J, Lee SY, Ko SK, Ro J.
Asia Pac J ClinOncol.2012 Sep; 8(3): 282-91.

5. Clinical heterogeneity of extranodal NK/T cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.

Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, Kim HJ, Kim SY, Kim CS,
Kim S, Kim JS, Sohn SK, Song HH, Lee JL, Kang YK, Kim CY, Lee WS, Yuh YJ, Kim
CS, Heo DS.

Ann Oncology.2008 Aug; 19(8): 1477-1484.